©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 7, 2016; 22(13): 3547-3557
Published online Apr 7, 2016. doi: 10.3748/wjg.v22.i13.3547
Published online Apr 7, 2016. doi: 10.3748/wjg.v22.i13.3547
Liver cancer stem cell markers: Progression and therapeutic implications
Jing-Hui Sun, Qing Luo, Ling-Ling Liu, Guan-Bin Song, Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, China
Author contributions: Sun JH designed the main concepts and wrote, revised the manuscript; Song GB supervised the writing, drafting and critical revision and final approval of the final version; Luo Q and Liu LL provided scientific and technical knowledge.
Supported by The Natural National Science Foundation of China, No. 11272365.
Conflict-of-interest statement: We declare that the authors have no conflict of interest.
Correspondence to: Guan-Bin Song, PhD, Professor of Biomedical Engineering, Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, No.174, Shapingba Street, Shapingba District, Chongqing 400044, China. song@cqu.edu.cn
Telephone: +86-23-65102507 Fax: +86-23-65102507
Received: December 21, 2015
Peer-review started: December 22, 2015
First decision: January 28, 2016
Revised: February 12, 2016
Accepted: March 2, 2016
Article in press: March 2, 2016
Published online: April 7, 2016
Processing time: 97 Days and 15.4 Hours
Peer-review started: December 22, 2015
First decision: January 28, 2016
Revised: February 12, 2016
Accepted: March 2, 2016
Article in press: March 2, 2016
Published online: April 7, 2016
Processing time: 97 Days and 15.4 Hours
Core Tip
Core tip: Liver cancer is the fifth most common cancer and the third leading cause of cancer-related mortality worldwide despite remarkable progress in understanding hepatocarcinogenesis and new therapeutic approaches. Recently, the presence of highly resistant cancer stem cells (CSCs) in liver cancer has been proposed to be responsible for tumor growth, invasion, metastasis and recurrence. CSC involvement in liver cancer pathogenesis also highlights them as preferential targets for therapy. This review specifically focuses on the markers used to define human liver cancer stem cells, the therapeutic implications of the expression of these markers in patient’s primary tumors, and the potential of the markers to serve as therapeutic targets.